Caricamento...
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3‐mutated (FLT3 (mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact of FLT3 mutation clearance and the achievement of composite complete remission (CRc) and complete remission/complete remission with par...
Salvato in:
| Pubblicato in: | Cancer Med |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7897940/ https://ncbi.nlm.nih.gov/pubmed/33340276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3652 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|